AYR-A:CNSX-Ayr Wellness Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | CNSX

Last Closing Price

CAD 6.03

Change

+0.15 (+2.55)%

Market Cap

CAD 0.42B

Volume

0.12M

Avg Analyst Target

CAD 8.38 (+38.89%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AYR-A Stock Forecast & Price:
Based on the Ayr Wellness Inc stock forecasts from 3 analysts, the average analyst target price for Ayr Wellness Inc is CAD 8.38 over the next 12 months. Ayr Wellness Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ayr Wellness Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Ayr Wellness Inc’s stock price was CAD 6.03. Ayr Wellness Inc’s stock price has changed by -7.09% over the past week, -5.93% over the past month and -83.43% over the last year.

About Ayr Wellness Inc (AYR-A:CA:CNSX)

Ayr Wellness Inc., a vertically-integrated cannabis multi-state operator, cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. The company's cannabis and cannabis products include concentrates, edibles, and vaporizer products. It also provi ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CURA:CA Curaleaf Holdings Inc

+0.11 (+1.44%)

CAD5.50B N/A 21.13
TRUL:CA Trulieve Cannabis Corp

+0.20 (+1.21%)

CAD3.23B 121.35 16.72
GTII:CA Green Thumb Industries Inc

+0.38 (+2.75%)

CAD3.13B 25.50 8.86
VRNO:CA Verano Holdings Corp

-0.13 (-1.83%)

CAD2.99B 13.46 N/A
HARV:CA Harvest Health & Recreation In..

N/A

CAD1.65B N/A 122.88
CL:CA Cresco Labs Inc

-0.20 (-4.30%)

CAD1.30B N/A -12.23
CCHW:CA Columbia Care Inc

-0.07 (-3.07%)

CAD0.86B N/A -26.36
PLTH:CA Planet 13 Holdings Inc

+0.04 (+1.67%)

CAD0.53B N/A 246.11
JUSH:CA Jushi Holdings Inc

N/A

CAD0.52B N/A 6.63
LHS:CA Liberty Health Sciences Inc

N/A

CAD0.51B 147.00 13.82

ETFs Containing AYR-A:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -68.50% 26% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.50% 26% F 20% F
Trailing 12 Months  
Capital Gain -82.85% 27% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.85% 27% F 16% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -22.15% 36% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.15% 36% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 34.01% 64% D 63% D
Risk Adjusted Return -65.13% 42% F 27% F
Market Capitalization 0.42B 92% A- 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.30 92% A- 93% A
Price / Cash Flow Ratio -15.01 86% B 81% B-
EV/EBITDA 8.32 13% F 7% F
Management Effectiveness  
Return on Equity -0.97% 92% A- 92% A-
Return on Invested Capital -8.89% 76% C 75% C
Return on Assets -0.79% 88% B+ 94% A
Debt to Equity Ratio 36.39% 25% F 18% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.47 17% F 15% F
Short Percent 0.83% 5% F 4% F
Beta 1.76 30% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.